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Background: There are several international guidelines on oxytocin regimens for induction and augmentation of
labour, but no agreement on a standardised regimen in Germany. This study collated and reviewed the oxytocin
regimens used for labour augmentation in university hospitals, with the long-term aim of contributing to the
development of a national clinical guideline.
Methods: Germany has 34 university hospital compounds, representing 39 maternity units. In this observational
study we asked units to provide standard operational procedures on oxytocin augmentation during labour or
provide the details in a structured survey. Data were collected on the dosage of oxytocin, type and volume of
solutions used, indications and contraindications for use and discontinuation, case-specific administration, and on
who developed the procedures. Findings were analysed descriptively.
Results: A total of 35 (90%) units participated in this study. Standard operating procedures were available in 24
units (69%), seven units (20%) did not have procedures and information was missing from four units (11%).
Midwives participated in the development of standard operating procedures in 15 units (43%). Infusions were most
commonly prepared using six units of oxytocin in 500 ml 0.9% normal saline solution (12 mU/ml). The infusions
were started at 120 mU/hour and increased by 120 mU/hour at 20-min intervals up to a maximum dosage of 1200
mU/hour. The most common indication for use was delayed progress in labour. Infusions were stopped when
uterine contractions became hypertonic and/or the fetal heart rate showed signs of distress. Most of the practices
described aligned with international guidance. All units used reduced oxytocin dosages for women with a history
of previous caesareans section, as recommended in the international guidelines, and restrictive use was advised in
multiparous women. The main difference between units related to combined use of amniotomy and oxytocin,
recommended by three guidelines but used in only four maternity units (11%).
Conclusions: While there was considerable variation in the oxytocin augmentation procedures, most but not all
practices used in these 35 German maternity units were comparable. Establishing a national guideline on the
criteria for and administration of oxytocin for augmentation of labour would eliminate the observed differences and
minimise risk of administration and medication error.
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There are several international guidelines on oxytocin
regimens used to induce or augment labour, but no
agreement on a standardised regimen in Germany. Dif-
ferent guidelines and publications report the use of low-
dose and high-dose regimens, and variations in regimens
used the same maternity unit depending on a practi-
tioner’s preferences [1–3]. Such variations, at national
and institutional level can be confusing and increase the
risk of errors and harms occuring [3, 4]. This study col-
lated and compared the standard operating procedures
(SOPs) used for augmentation of labour in 35 of the 39
university-based maternity units in Germany.
Background
In 1906, Sir Henry Dale showed that the hormone oxyto-
cin, in the form of a dried ox-pituitary extract, promoted
uterine contractions [5]. Oxytocin is a peptide with nine
amino acids, only two of which differ from the hormone
arginine vasopressin (AVP) [6], and was first synthesised
in 1953 by Vincent du Vigneaud et al. [7]. Due to the high
structural similarity of oxytocin and AVP, both hormones
signal through G-protein-coupled receptors, certain cross-
reactivity properties are evident [8]. Both hormones cause
muscle contractions, and are associated with sexuality,
anxiety, depression, cancer and social behaviour [9–11].
While AVP is known to, mainly, regulate vasoconstriction
[12], oxytocin is responsible for uterine muscle contract-
ibility during labour, and has been used for labour induc-
tion and augmentation for decades [13–15]. While slow
or no progress in labour, which are associated with in-
creased maternal and fetal morbidity [16], can be remed-
ied with oxytocin augmentation [15, 17], there is no
conclusive evidence that augmentation of labour with oxy-
tocin decreases caesarean section rates [16, 18].
The number of oxytocin receptors in the uterus is dy-
namic and increases as pregnancy approaches term. This
leads to a higher uterine sensitivity to oxytocin and
causes uterine contractions [19]. In contrast, a reduction
in the number of oxytocin receptors has been reported
in women receiving oxytocin for induction or augmenta-
tion of labour [19]. Oxytocin shows particular pharma-
codynamics and kinetics [15]; for example, its effect lasts
for approximately 10 minutes, but its half-life decreases
when plasma concentrations are increased with the use
of oxytocin infusions [20]. According to Clark et al. [21]
oxytocin has three distinctive characteristics. First, the
desired plasma level and effect is usually reached after
40 min [22]. Second, the safe and optimal dosage is chal-
lenging to determine because oxytocin has a variable de-
gree of efficiency [1, 2, 21, 23]. Third, artificially
inducing and/or increasing the rate and strength of uter-
ine contractions has an unpredictable effect on fetal oxy-
gen saturation [24].An intravenous high-dose bolus of oxytocin is recom-
mended immediately after the birth of the anterior shoul-
der to prevent postpartum haemorrhage [25]. After birth,
oxytocin plays an important role in maternal well-being,
bonding and lactation [24, 26, 27]. Reduced maternal oxy-
tocin levels and increased prolactin levels during breast-
feeding have been reported after in-labour oxytocin
infusion (exogenous oxytocin) [24]. In one study, women
who were breastfeeding their babies and who received ex-
ogenous oxytocin during labour showed reduced levels of
anxiety and aggression, traits associated with endogenous
oxytocin [27]. In addition, depressed reflexes associated
with breastfeeding in newborns and oxytocin infusion dur-
ing labour have been reported [28, 29]. Consequently, the
administration of oxytocin during labour appears to have
long-lasting effects on mother and child [30].
Overall, oxytocin has particular pharmacodynamic and
kinetic characteristics with versatile effects on the human
body [15]. Exogenous oxytocin administration can cause
various side-effects, such as hyperactive uterine activity,
even uterine rupture, and fetal hypoxia [15, 31, 32]. Stud-
ies reporting on women who have intrapartum oxytocin
augmentation are very rare [33]. In 2007, the Institute for
Safe Medication Practices (ISMP) added oxytocin to the
list of high-alert medications, and urged caution with its
administration during labour [21, 34]. Consequently, hav-
ing a clinical guideline on the use of oxytocin for inducing
and/or augmenting labour is the first step towards safer
administration [18, 31, 35–37], and has the potential to
eliminate inter-institutional variations [3] and minimise
the risk of administration errors.
There are a number of international and national guide-
lines and recommendations on oxytocin administration
for labour induction and augmentation (summarised in
Table 1). These include: the Irish guideline, developed by
the Health Service Executive (HSE) on Oxytocin to accel-
erate or induce labour [37]; the National Institute for
Health and Care Excellence (NICE) guideline on Intrapar-
tum care for healthy women and babies [35]; the Nordic
Federation of Societies of Obstetrics and Gynaecology
(NFOG) guideline on Augmentation of labour [36]; the
American Congress of Obstetricians and Gynaecologists
(ACOG) practice bulletin number 107 on Induction of
labour [31], and the French recommendations on Oxyto-
cin administration during spontaneous labour, developed
by the CNGOF (French National College of Gynecologists
Obstetricians) and the CNSF (National College of Mid-
wives) [38]. These guidelines vary regarding the starting
dose of international units (U) used; fluid type and vol-
ume; minimum, escalation and maximum dosages, and es-
calation time intervals. Most of the guidelines recommend
performing an amniotomy prior to commencing an oxyto-
cin infusion while all guidelines mention uterine hyper-
activity as a contraindication for continued use. Further
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defined criteria to start or stop oxytocin infusion during
labour. Case-specific recommendations in relation to par-
ity, uterine scars, term, preterm and twin pregnancies are
usually provided.
In Germany, there are no guidelines or national data
on intrapartum oxytocin augmentation. Due to the lim-
ited information, and in order to be able to contribute to
a national guideline, this study aimed to describe the
most common clinical practice patterns on oxytocin
augmentation during labour.
Methods
Setting
All 34 university compounds in Germany were surveyed.
Five university hospitals have campuses with two separate
maternity units, and these were treated as independent
units resulting in a total of 39 maternity units. The clinical
director of the university gynaecological hospitals, senior
physicians and head midwives were contacted by e-mail.
All participating units were obstetrician-led units [39].
The tool
This survey is part of a larger international, unfunded
survey, which was initiated during the EU COST Action
IS1405 on organizational perspectives (http://www.cost.
eu/COST_Actions/isch/IS1405; https://eubirthresearch.
eu/). The survey was translated from a 20-item survey
that was based on the tool used to capture institutional
practices on oxytocin acceleration or induction of labour
in Ireland [37, 40]. The questionnaire was originally de-
signed according to the NHSLA/CNST standard 2 criter-
ion 5 of the Maternity Clinical Risk Management
Standards. Therefore, it included the following five cat-
egories: oxytocin dosage, criteria for oxytocin adminis-
tration and indications, contraindications, case-specific
conditions and the process of developing SOPs. Add-
itional file 1: Table S1 shows the questionnaire and the
NHSLA use of oxytocin can be found online (http://
workplacehealthandwellbeing.co.uk/publication/syntoci-
non-infusion-regime-io25v2/). The survey was not piloted
but maternity care practitioners in eleven countries, ten
European and South Africa, reviewed the content for accur-
acy and completeness.
Ethical approval
The study and research protocol were approved by the
Ethical Review Board of Hannover Medical School (no.
3317–2016).
Data collection
The study information, survey and consent forms were
sent electronically in August 2016. Participating units
could choose to complete the survey or forward theirSOP to the research team. Written consent was obtained
from all participants. When SOPs alone were received,
data were entered into the data collection form by SH.
Hospitals’ names were removed.
Data preparation
Some responses contained more than one answer re-
garding oxytocin dosages used and titration rates. In
those cases, all responses were reviewed. For ease of in-
terpretation and comparison, we converted dosage infor-
mation to mU/hour. After conversion, the median
starting dosage of 120 mU/h correlated to 2mU/min. In
turn, this equated to 10 ml/hour or 0.16 ml/minute when
the solution was prepared with 6 U oxytocin in 500 ml
of fluid (oxytocin concentration of 12 mU/ml).
Statistical analysis
Data were analysed descriptively using GraphPad Prism
7. Frequencies were used to summarise categorical data:
international oxytocin units, volume, infusion fluid and
final oxytocin concentration. Continuous data were sum-
marised using the mean distribution: starting, maximum
and escalation dosage.
Results
A total of 35 out of 39 (90%) maternity units returned
the survey and/or SOP.
Twenty-five units (71%) completed the survey alone,
six (17%) completed the survey and sent their SOPs and
4 units (11%) sent the SOP alone.
Development of standard operational procedures
Almost half of the SOPs (44%, n = 16) were developed
by (senior) consultants (34%, n = 12) or the assistant
medical director and/or the head of the department of
obstetrics (11%, n = 4). Three SOPs (9%) were developed
by (head) midwives, with input from the assistant med-
ical director or the head of the department. Another
three procedures (9%) were developed jointly by (senior)
physicians and (head) midwives and 2 units (6%) stated
that the entire obstetric and midwifery team developed
the SOP.
Midwives participated in the development of SOPs in
less than half of the units (43%, n = 15), while 9 units
(26%) reported no midwifery involvement. No SOP was
available in 7 units (20%) and information was missing
from 4 units (11%).
Conditions to start and monitor oxytocin administration
for labour augmentation
The main indication given for augmenting labour with oxy-
tocin was delayed progress during labour (31%, n = 11). Cri-
teria included prolonged first stage of labour (23%, n = 8) or
prolonged second stage of labour, delayed progress with or
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In another 11% of the units (n = 4) the administration of
oxytocin was specifically prescribed by a physician, while
the criteria for starting oxytocin administration were up to
the individual physician (6%, n = 2) and women’s written
consent was required in 6% of the units (n = 2).
After oxytocin infusions were started, continuous car-
diotocography (CTG) was used to monitor labour in 23
units (66%). CTG was continued for 30 min in 12 units
(52%), while the remaining units stated no further infor-
mation on CTG monitoring. Three units also used ultra-
sonography, took fetal blood samples or performed
vaginal examination (3%, n = 1 for each criterion) to
evaluate the obstetric situation. Four units (11%) re-
ported no defined indications or criteria, and data on
starting criteria were missing for two units (6%).
Although the survey asked specifically about indica-
tions for oxytocin administration to augment labour,
additional details on induction of labour was reported by
five units (14%), delivery of the placenta by one unit
(3%) and accelerating uterine contractions after the birth
of the first twin by three units (9%).
Preparation of oxytocic infusion
The preparation of oxytocin infusions varied in relation
to the number of international units used, and the type
and quantity of the infusion fluid (Fig. 1). More than 50%
of the units (n= 20) prepared oxytocin infusions using 6U
while another twelve (32%) used 3U (Fig. 1a). Three of the
SOPs gave two alternative oxytocin dosages (3U or 6U), giv-
ing a total of 38 responses (total n= 35 + 3). The majority of
maternity units use a volume of 500mls (72%, n= 26) (Fig.
1b). One SOP gave a two-volume option, 250ml or 500ml
(total n= 35 + 1). Normal saline was the most commonly
used infusion fluid (n= 20, 54%) (Fig. 1c) and two units spe-
cified two fluid options, resulting in a total of 37 responses
(total n= 35 + 2).
When converted to U/ml, the oxytocin concentra-
tion in 55% (n = 21) of units was set to12mU/ml
(Fig. 1d). Overall, the concentration ranged from 6
mU/ml to 200 mU/ml. Two alternative oxytocin
dosage regimens in three protocols resulted in add-
itional three data points (total n = 35 + 3).
Oxytocin dosage
Starting, escalation and maximum dosages, as well as es-
calation intervals, were compared (Fig. 2). The median
concentration of the starting dosage and the escalation
dosage was 120 mU/h, stated by 37% (n = 14/38) and
29% (n = 11/38) of units, respectively (Fig. 2a, b). In con-
trast, the maximum dosage showed greater variation
with a median concentration of 1200 mU/h (31%, n = 11/
35) (Fig. 2c). Escalation intervals varied between 20
(34%, n = 12), 15 (17%, n = 6) and 30 min (11%, n = 4).Only a few maternity units stated a time range, the most
common range being 15–20min (9%, n = 3).
Titration of oxytocin dosage
Oxytocin dosage was titrated with uterine contractions
in 29 units (83%). One unit (3%) stated it was not ti-
trated and data were missing from five units (14%). Uter-
ine contractions were monitored by continuous CTG in
26 units (74%) while two units (6%) used intermittent
tocometry. In four units, uterine contractions were mon-
itored every 10min (n = 3) or every 30 min (n = 1) but
the method(s) used were not specified. One unit stated
the frequency of monitoring contractions varied (3%).
Data were missing for two units (6%).
Contraindications and criteria for stopping intrapartum
oxytocin infusions
The most commonly stated contraindication was a
pathological cardiotocograph (CTG), stated by 10 units
(29%). Overall, oxytocin administration was contraindi-
cated when vaginal birth and/or uterine contractions
were contraindicated (20%, n = 7). These included the
following contraindications: cephalopelvic disproportion
and mechanical obstruction, placenta or vasa praevia,
active herpes genitalis, abruption of the placenta, abnor-
mal lie or position of fetus (e.g. transverse), maternal
heart defects/problems, prolapse of the umbilical cord as
well as a suspected fetal asphyxia.
Further contraindications included uterine hyperactivity
(17%, n = 6) and having had a previous caesarean section
or any further uterine surgery (14%, n = 5), risk for uterine
rupture and fetal heart rate abnormalities or problems
(both 11%, n = 4).
Several units gave multiple responses. Four maternity
units gave no contraindications for oxytocin (11%), and data
were missing from another four university hospitals (11%).
The criteria for stopping oxytocin infusion were
grouped according to reasons: fetal (83%, n = 29),
placental (17%, n = 6), uterine (69%, n = 24), maternal
(17%, n = 6) and others (26%, n = 9). Overall, a
pathological CTG and hyperstimulation of the uterus
were the most frequently given criteria, stated by 21
units (60%), and another 10 units (29%) gave shoul-
der dystocia as a criterion. Data were missing from 3
units (9%).
In summary, a total of 30 different contraindications
for oxytocin augmentation were reported and 35 cri-
teria for discontinuing oxytocin infusion. Multiple an-
swers were given in most cases.
Alterations in oxytocin administration in case-specific
circumstances
Oxytocin administration regimens can differ depending
on case-specific conditions such as parity and previous
A B C
D
Fig. 1 Descriptive analysis of oxytocin preparation and concentration in German university hospitals. The frequencies of used international
oxytocin units (a), the volume in ml (b) and the fluid it was prepared in (c) as well as the final oxytocin concentrations in mU/ml (d) are depicted.
(NaCl: Sodium chloride; E 153: electrolyte infusion solution 153)
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mendations were reported for primiparous and multipar-
ous women in any unit, or for women in preterm labour
in 66% of units (n = 23). Women with a twin pregnancy
were advised to receive an oxytocin infusion to augment
labour according to standard protocols in 49% of units
(n = 17).A B
Fig. 2 Range of oxytocin dosage for labour augmentation in German unive
maximum (b) and escalation dosage (c) in mU/hProtocols varied for women with uterine scars: 37%
(n = 13) of the units used lower oxytocin dosages, slower
escalation rates or reduced maximum dosages. Among
others, additional recommendations were monitoring with
CTG (14%, n = 5), consultation with an obstetrician (6%,
n = 2), ultrasonography of the uterine scar or delaying the
oxytocin infusion until later in labour (both 3%, n = 1).C
rsity hospitals. This Figure contains the frequencies of starting (a),
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included restrictive administration of oxytocin (12%,
n = 4) before, and increase in oxytocin, administration
after the birth of the first twin (9%, n = 3), and oxyto-
cin administration in combination with CTG monitor-
ing (6%, n = 2).
Individually adjusted recommendations were stated for
approximately 10% of case-specific alterations.
Discussion
This study demonstrated considerable variation in the
intrapartum oxytocin infusion regimens used in German
university hospitals. Regimens differed widely in several
aspects, including indications for administration and
preparation of oxytocin solutions. Overall, most university
hospitals prepared oxytocin solutions with 6 U (53%, n =
20), in 500ml of intravenous fluids (72%, n = 20), which
resulted in an oxytocin concentration of 12mU/ml. TheTable 1 International guidelines for the administration of oxytocin
HSE (Ireland) NICE (Great
Britain)
NFOG (Denmark
Finland, Iceland,
International
Units (U)
10 / 5
Oxytocin
solution
1 l NaCl / 500 ml NaCl
Oxytocin
concentration
(mU/ml)
10 / 10
Start dosage
(mU/h)
60–300 / 360
Maximum
dosage (mU/
h)
1800 4–5
contractions/
10 min
2400
Escalation
dosage (mU/
h)
60–300 / 180
Time interval
(min)
15–30 30 15
Monitoring CTG CTG CTG
Criteria for
oxytocin
administration
20min CTG, stable fetal
status, preceding
amniotomy
CTG,
preceding
amniotomy
CTG, preceding
Indication Slow labour, reduced
contraction frequency
Slow labour,
reduced
contraction
frequency
in-effective cont
Contra-
indications
Fetal distress, hyperactive
uterus, uterus scar, fetal
malposition
Hyperactive
uterus
Hyperactive ute
dystocia
Case-specific
variations
Multipara, uterus scar, pre-
term labour, twin preg-
nancy, maternal heart
insufficiencies
Multipara,
regional
analgesia
Sensitivity is ind
women and the
should be adap
uterus scarmost commonly used infusion fluid was 0,9% NaCl (54%,
n = 20). These results fall into the ranges reported in the
HSE, NICE, NFOG and ACOG guidelines: 5-30 U in 500-
1000ml NaCl or Ringer lactate, but they differ in the exact
values and infusion fluids (Table 1) [31, 35–37]. We identi-
fied varying indications, contraindications and case-specific
guidelines for intrapartum oxytocin administration in most
of the maternity units. Moreover, our study depicts the
magnitude of inter-institutional variations for augmenting
labour using oxytocin [3]. Although there is no recommen-
dation on the superiority of one regimen over others [1, 2],
such variations pose challenges for clinicians, the mother
and the unborn as well as the reproducibility of favourable
outcomes.
To identify similarities and differences with other
countries, we compared our findings with the inter-
national guidelines in relation to indications for starting
augmentation; monitoring uterine activity during labour, Sweden,
Norway)
ACOG (USA) Empiric study on
German
university units
(n = 35)
30 6
500ml Ringer lactate 500 ml NaCl
60 12
120 120
9000 1200
120 120
30 20
CTG CTG
amniotomy Stable fetal and maternal status,
continuous monitoring
CTG, monitoring
of obstetric
situation
ractions Induction and augmentation of
labour
Labour
augmentation
rus, shoulder Hyperactive uterus, water
intoxication, fetal distress, no
monitoring possible
Pathological
CTG, hyperactive
uterus, shoulder
dystocia
ividual for every
administration
ted accordingly,
After amniotomy reduction of
oxytocin dosage, guideline for:
singletons, vertex, in term,
without uterus scars
Uterus scar, twin
pregnancy
(multipara, pre-
term)
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contraindications for use, criteria for stopping the infu-
sion and criteria for alterating the regimen.
Conditions to start and monitor oxytocin administration
for labour augmentation
The main focus of the study was the intrapartum admin-
istration of oxytocin for labour augmentation. The 35
maternity units that participated in our study stated de-
layed progress of labour was the main indication for
augmentation with oxytocin, but there was no clear def-
inition of delayed progress in labour. Differing criteria
can be also found in other guidelines. For example,
NFOG advises oxytocin acceleration when cervical dila-
tation is less than 1 cm/hour after 2 hours in the active
phase in nulliparous women, and after 4 hours in mul-
tiparous women [36]. According to NICE (2017), delayed
labour progress is assessed by 1) cervical dilatation of
less than 2 cm in 4 h in a first labour, 2) cervical dilata-
tion of less than 2 cm in 4 h or a reduction in labour
progress for second or subsequent labours, 3) delay in
descent and rotation of the fetal head, 4) and changes in
the strength, duration and frequency of uterine contrac-
tions [35].
Oxytocin augmentation is one component of the ac-
tive management of labour package which was intro-
duced in Dublin in the 1960s [41]. Labour progress is
different in nulliparous and multiparous women, dif-
ferences which have been acknowledged already for
decades [42]. The normal progress of labour was in-
vestigated by Friedman [43] and re-evaluated more
recently by Zhang [44, 45]. Recent studies on the use
of the partogram to monitor fetal and maternal key
data during labour showed that they can minimise
the administration of oxytocin without impacting
negatively on progress of labour in terms of frequency
of operative births and safety criteria such as the
Apgar score [46]. This is especially interesting as the
administration of oxytocin alone did not reduce the
need for operative births [46, 47], in contrast to early
amniotomy and oxytocin augmentation together [48].
It is still not clear if delayed oxytocin administration
would contribute to an increase in spontaneous birth
[49]. In recent years, research on oxytocin focussed
on negative effects on children’s development. For ex-
ample, synthetic oxytocin was suspected to effect
hyperactivity/inattention problems in children, even
though the data did not support the hypothesis [50].
Preparation of oxytocin infusion, dosage and titration
The most frequently used starting dosage was 120mU/h
with a median maximum dosage of 1200 mU/h. The
most frequently used escalation dosage was 120mU/h,
and the most frequently used escalation interval was 20minutes. Both starting and escalation dosages correlate
with the ACOG guideline but the median maximum
dosage in German university hospitals is lower com-
pared to all four guidelines (Table 1) [31]. A Cochrane
review found a reduced labour duration and increase in
spontaneous births when a higher starting and escalation
dosage was used [2]. This was defined as 4 mU/min or
more, which is achieved with 6 U oxytocin in 500ml
NaCl and a starting and escalation dosage of 20 ml/h.
This regimen was only recommended by NFOG and was
included in the range of dosage in the HSE guidelines
[36, 37]. No increased side effects of high oxytocin
starting dosages were found (instrumental vaginal birth,
epidural analgesia, hyperstimulation of the uterus, post-
partum haemorrhage, chorioamnionitis, women’s per-
ceptions of experiences, Apgar scores, umbilical cord
pH, admission to special care baby unit, neonatal mor-
tality) [2]. Nevertheless, the review authors concluded
that they could not give a general recommendation for a
high-dose regimen because of insufficient evidence [2].
The escalation interval of 20 min lies in the recom-
mended range of 15–30min. Nevertheless, oxytocin has
been shown to reach the desired plasma level after ap-
proximately 40 min [20] and dosage should only be in-
creased after 30 min or later according to NICE and
ACOG [31, 35]. Hence, variation in the escalation time
interval may increase unintended side effects.
The ACOG guideline recommends fetal heart rate ob-
servation using continuous electronic CTG for 20–30
min prior to starting oxytocin administration, and the
HSE guideline states CTG should be performed for at
least 20 min [31, 37] which is similar to our findings
(Table 1). A total of 23 maternity units (66%) monitored
the fetal heart rate using CTG; 52% (n = 12) for a
duration of 30 min and 9% (n = 2) for 20 min. Oxyto-
cin dosage was titrated with uterine contractions in
83% (n = 29) of the units, and uterine activity was
monitored with continuous CTG in 74% (n = 26). In-
fusion titration with uterine contractions minimise
the risk and consequences of uterine hyperstimula-
tion. The NICE guideline recommends achieving 4–5
contractions in 10 min [35] and NFOG recommends a
rate of 3–5 in 10 min [36].
Three out of four guidelines recommend performing
an amniotomy before starting an oxytocin infusion. In
our survey, only 4 units (11%) gave previous amniotomy
as a criterion to start oxytocin (Table 1). Previous studies
comparing the use of amniotomy to no treatment
showed a reduced labour duration of two hours, but
no reduction in the number of caesarean sections
performed [16]. In a review of 11 trials, performing
amniotomy prior to oxytocin administration was asso-
ciated with a modest reduction in the number of cae-
sarean births [51], and labour duration was reduced
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als; 4816 women) [51]. Hence, the impact of a combined
use of amniotomy and oxytocin on labour progression
and caesarean section rates needs to be investigated
further.
Contraindications and criteria for intrapartum oxytocin
cessation
The recommendations for oxytocin administration in exist-
ing guidelines vary depending on the women’s specific
conditions. Hyperstimulation is defined as more than 7 uter-
ine contractions in 15minutes in nulliparous women and
more than 5 contractions in 15minutes in multiparous
women, according to HSE guideline [37]. The ACOG guide-
lines define more than 5 contractions in 10minutes,
averaged over a 30-min interval [31]. NFOG defines hy-
perstimulation as more than 5 contractions in 10minutes
or a duration of the contraction with more than 2minutes
[36]. Not all units used CTG monitoring, but four inter-
national guidelines recommended its use to detect fetal
heart rate changes, a contraindication to starting and a
criterion for stopping oxytocin infusion in most of the
units (83%; Table 1).
Further contraindications included general contraindi-
cations for vaginal birth. These criteria can also be found
in international guidelines, such as ACOG (placenta/
vasa praevia, transverse fetal lie, umbilical cord prolapse,
previous classical caesarean delivery, active genital her-
pes infection, previous myomectomy entering the endo-
metrial cavity) [31].
Alterations in oxytocin administration in case-specific
circumstances
Several units stated that oxytocin should be used with
caution when there was a history of previous uterine sur-
vey. This is supported by studies which showed an in-
creased dose-dependent risk of uterine rupture with
oxytocin [52]. A maximum dosage of 20mU/min was rec-
ommended, achieved at a rate of 100ml/h when 6 U oxy-
tocin is added to 500ml NaCl [52]. Specific guidelines for
management of vaginal birth after caesarean section
(VBAC) did not include a maximum dosage [53, 54].
However, two guidelines advised clinical assessment
by a senior obstetrician before augmentation during
the first stage of labour [35, 37]. In addition, the HSE
guideline does not recommend oxytocin administra-
tion use in the second stage of labour in women with
uterine scars [37].
Recommendations for women with twin pregnancies in-
cluded a restrictive administration of oxytocin before (9%,
n = 3), and an increase in oxytocin dosage after (11%, n =
4), the birth of the first twin. These results are in line with
the hypothesised increase of contraction frequency and
overall response to oxytocin with increased birth weightand degree of tissue stretching during a twin pregnancy
[23]. A restrictive administration at the start of the infu-
sion reduces the risk of oxytocin overdose and associated
side-effects while the dosage can be increased after the
birth of the first twin when the uterine size and conse-
quently the level of stretch decreases and an increase in
uterine contractions is desirable. Only the HSE guidelines
mentioned twin pregnancies and recommended CTG
monitoring for both twins and starting oxytocin when
prescribed by a senior obstetrician [37].
Furthermore, both the HSE and NICE guidelines ad-
vise restrictive use of oxytocin in multiparous women,
and the NICE guideline states that an obstetrician
should perform a full assessment and a vaginal examin-
ation before the decision to use oxytocin is made [35].
Four units reported restricted use of oxytocin ad-
ministration in preterm labour. This is supported by
the HSE guideline, which in general advise caution
with oxytocin [37].Limitations
There were a number of limitations to our study. It was
designed to describe current practices in German uni-
versity hospitals and compare these with international
guidelines. We did not collect additional hospital-level
data; therefore, we were unable to explore multiple asso-
ciations between variables.
Our study is based on a national cohort and data ac-
quired in Germany may not be applicable to other coun-
tries. The statistical analyses performed are limited due
to the small number of hospitals included. In addition,
there may be a selection bias as only university hospitals
were asked to participate, and the population of child-
bearing women in these hospitals may differ from those
in other hospitals. Care and practice may also differ in
other German non-university maternity hospitals. How-
ever, to contextualise the findings, we compared prac-
tices with other international guidelines.
One further limitation exists because of missing data
from some units, especially on contraindications for oxy-
tocin administration. While it can be suggested that
contraindications for spontaneous labour are also contra-
indications for oxytocin augmentation, units did not re-
port on these in the survey or include them in their SOPs.
The French recommendations for the use of oxytocin
during spontaneous labour were published after this
study had been finalised [38]. These recommendations
were developed jointly by the CNGOF (French National
College of Gynecologists Obstetricians) and the CNSF
(National College of Midwives) and used in 2018 by the
HAS (High Authority of Health) in guidelines on normal
birth. In future studies this guideline should be included
in the overall evaluation process [38].
Helbig et al. BMC Pregnancy and Childbirth          (2019) 19:238 Page 9 of 10Conclusion
Our study showed a wide variation in oxytocin administra-
tion and also in the completeness of the SOPs in the hospi-
tals surveyed. Labour wards, including midwife-led units,
should have SOPs, which state the infusion solution, start-
ing and escalation dosage of oxytocin, and indications and
contraindications. Protocols should identify procedures to
be followed in specific circumstances (VBAC, twins, etc.) to
improve safety for women and babies. The development of
a national guideline would help midwives and obstetricians
to adopt them for their hospital-specific SOP and daily
practice, and eliminate inter-institutional variations. CTG
monitoring before (for 20-30min) and during oxytocin in-
fusion should be considered standard, while performing an
amniotomy before starting an oxytocin infusion needs fur-
ther investigation. Overall, a national guideline would help
clinicians clinicians develop clear local guidelines on the
criteria for oxytocin augmentation of labour, and thereby
help minimise medication and administration errors.
Additional file
Additional file 1: Table S1. The questionnaire was used in the national
survey: Inter-institutional variations in oxytocin augmentation during
labour in German university hospitals. It was originally designed
according to the NHSLA/CNST standard 2 criterion 5 of the Maternity
Clinical Risk Management Standards. Therefore, it includes the following
five categories: oxytocin dosage, criteria for oxytocin administration and
indications, contraindications, case-specific conditions and the process of
developing SOPs. (XLSX 11 kb)
Abbreviations
ACOG: American Congress of Obstetricians and Gynaecologists;
AVP: Arginine vasopressin; CTG: Cardiotocography; HSE: Health Service
Executive; ISMP: Institute for Safe Medication Practices; NFOG: Nordic
Federation for Societies of Obstetrics and Gynaecology; NICE: National
Institute for Health and Care Excellence; SOP: Standard operating procedures;
U: International units; VBAC: Vaginal birth after caesarean section
Acknowledgements
This study is part of the EU COST Action IS1405: ‘Building Intrapartum
Research Through Health - an interdisciplinary whole system approach to
understanding and contextualising physiological labour and birth (BIRTH)’.
Authors’ contributions
SH: Data acquisition and handling, manuscript writing. AP: Study initiation, data
acquisition, manuscript revision. ES: Data handling, manuscript revision. DD:
Study initiation, manuscript revision. MMG: Study initiation, data acquisition,
manuscript revision. All authors read and approved the final manuscript.
Funding
No funding was available for this study.
Availability of data and materials
All data generated or analysed during this study are included in this
published article. The anonymised, original datasets used during the current
study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
Written consent was obtained from all participants.
The study and research protocol were approved by the Ethical Review Board
of Hannover Medical School (no. 3317–2016), and the study was exempt
from full review.Consent for publication
Not applicable.
Competing interests
Mechthild M. Gross is a member of the editorial board (Associate Editor) of
BMC pregnancy and childbirth. Otherwise, the authors declare that they
have no competing interests.
Author details
1Midwifery Research and Education Unit, Department of Obstetrics,
Gynaecology & Reproductive Medicine, Hannover Medical School,
Carl-Neuberg-Str. 1, D – 30625 Hannover, Germany. 2School of Nursing and
Midwifery, Trinity College Dublin, 24 D’Olier Street, Dublin D02 T283, Ireland.
Received: 14 December 2017 Accepted: 31 May 2019
References
1. Manjula BG, Bagga R, Kalra J, Dutta S. Labour induction with an
intermediate-dose oxytocin regimen has advantages over a high-dose
regimen. J Obstet Gynaecol (Lahore) 2015;35(4):362–7. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/25384080.
2. Kenyon S, Tokumasu H, Dowswell T, Pledge D, Mori R. High-dose versus
low-dose oxytocin for augmentation of delayed labour. Cochrane database
Syst Rev 2013;7(7):CD007201. Available from: https://www.ncbi.nlm.nih.gov/
pubmed/23853046.
3. Plough AC, Galvin G, Li Z, Lipsitz SR, Alidina S, Henrich NJ, et al. Relationship
between labor and delivery unit management practices and maternal
outcomes. Obstet Gynecol. 2017;0(0):1–8.
4. Rohn AE, Bastek JA, Sammel MD, Wang E, Srinivas SK. Unintended clinical
consequences of the implementation of a checklist-based , low-dose
oxytocin protocol. Am J Perinatol. 2015;32:371–8.
5. Dale HH. On some physiological actions of ergot. J Physiol. 1906;34(3):163–206.
6. Goodson JL. Nonapeptides and the evolutionary patterning of sociality.
Prog Brain Res. Elsevier. 2008;170:3–15 Available from: http://linkinghub.
elsevier.com/retrieve/pii/S0079612308004019.
7. du Vigneaud V, Ressler C, Swan CJM, Roberts CW, Katsoyannis PG, Gordon S.
The synthesis of an octapetide amide with the hormonal activity of
oxytocin. J Am Chem Soc. 1953;75(19):4879–80.
8. Arrowsmith S, Wray S. Oxytocin: its mechanism of action and receptor
signalling in the myometrium. J Neuroendocrinol. 2014;26(6):356–69.
9. Neumann ID, Landgraf R. Balance of brain oxytocin and vasopressin: implications for
anxiety, depression, and social behaviors. Trends Neurosci. Elsevier Ltd. 2012;35(11):
649–59 Available from: https://doi.org/10.1016/j.tins.2012.08.004.
10. Cassoni P, Marrocco T, Deaglio S, Sapino A, Bussolati G. Biological relevance
of oxytocin and oxytocin receptors in cancer cells and primary tumors. Ann
Oncol. 2001;12:37–9.
11. Bendix M, Uvnäs-Moberg K, Petersson M, Gustavsson P, Svanborg P, Åsberg
M, et al. Plasma oxytocin and personality traits in psychiatric outpatients.
Psychoneuroendocrinology. Elsevier Ltd. 2015;57:102–10 Available from:
https://doi.org/10.1016/j.psyneuen.2015.04.003.
12. Webb L, Brody J, Webb RL. Evidence for a central role for vasopressin in
cardiovascular regulation. Am Physiol Soc. 1983;244(6):852–9.
13. Sogolow SR. An historical review of the use of oxytocin prior to delivery.
Obstet Gynecol Surv. 1966;21(2):155–72.
14. Watson B. Further experience with pituitary extract in the induction of
labor. Am J Obstet Gynecol. 1922;4(6):603–8.
15. Simpson KR. Clinicians’ guide to the use of oxytocin for labor induction and
augmentation. J Midwifery Women’s Heal. 2011;56(3):214–21.
16. Bugg GJ, Siddiqui F, Thornton JG. Oxytocin versus no treatment or delayed
treatment for slow progress in the first stage of spontaneous labour. In: Bugg GJ,
editor. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons,
Ltd; 2013. Available from: http://doi.wiley.com/10.1002/14651858.CD007123.pub3.
17. Dawood MY. Pharmacologic stimulation of uterine contraction. Semin
Perinatol. 1995 [cited 2017 Jan 23];19(1):73–83. Available from: http://
linkinghub.elsevier.com/retrieve/pii/S0146000595800492
18. (WHO) World Health Organization. WHO recommendations for
augmentation of labour. WHO Library. 2014.
19. Phaneuf S, Rodríguez Liñares B, TambyRaja RL, MacKenzie IZ. López Bernal a.
loss of myometrial oxytocin receptors during oxytocin-induced and
oxytocin-augmented labour. J Reprod Fertil. 2000;120(1):91–7.
Helbig et al. BMC Pregnancy and Childbirth          (2019) 19:238 Page 10 of 1020. Yusoff Dawood M, Ylikorkala O, Trivedi D, Gupta R. Oxytocin levels and
disappearance rate and plasma follicle-stimulating hormone and
luteinizing hormone after oxytocin infusion in men. J Clin Endocrinol
Metab. 1980;50(2):397–400.
21. Clark SL, Simpson KR, Knox GE, Garite TJ. Oxytocin: new perspectives on an
old drug. Am J Obstet Gynecol. Mosby, Inc. 2009;200(1):35.e1–6 Available
from: https://doi.org/10.1016/j.ajog.2008.06.010.
22. Seitchik J, Amico J, Robinson AG, Castillo M. Oxytocin augmentation of
dysfunctional labor. Am J Obstet Gynecol. 1984 [cited 2017 Jan 27];150(3):
225–228. Available from: http://linkinghub.elsevier.com/retrieve/pii/
S0002937884903557
23. Turton P, Arrowsmith S, Prescott J, Ballard C, Bricker L, Neilson J, et al. A
comparison of the contractile properties of myometrium from singleton
and twin pregnancies. PLoS One. 2013;8(5):e63800, https://doi.org/10.1371/
journal.pone.0063800.
24. Jonas K, Johansson LM, Nissen E, Ejdebäck M, Ransjö-Arvidson a B, Uvnäs-
Moberg K. Effects of intrapartum oxytocin administration and epidural analgesia
on the concentration of plasma oxytocin and prolactin, in response to suckling
during the second day postpartum. Breastfeed Med. 2009;4(2):71–82.
25. Gallos ID, Williams HM, Price MJ, Merriel A, Gee H, Lissauer D, et al.
Uterotonic agents for preventing postpartum haemorrhage: a network
meta-analysis. Cochrane Database Syst Rev. 2018;(4) Available from: http://
doi.wiley.com/10.1002/14651858.CD011689.pub2.
26. Bell AF, Erickson EN, Carter CS. Beyond labor: the role of natural and
synthetic oxytocin in the transition to motherhood. J Midwifery Women’s
Heal. 2014;59(1):35–42.
27. Jonas W, Nissen E, Ransjö-Arvidson AB, Matthiesen AS, Uvnäs-Moberg K. Influence
of oxytocin or epidural analgesia on personality profile in breastfeeding women:
a comparative study. Arch Womens Ment Health. 2008;11(5–6):335–45.
28. Olza Fernández I, Marín Gabriel M, Malalana Martínez A, Fernández-Canadas
Morillo A, López Sánchez F, Costarelli V. Newborn feeding behaviour
depressed by intrapartum oxytocin: a pilot study. Acta Paediatr Int J
Paediatr. 2012;101(7):749–54.
29. Marín Gabriel MA, Olza Fernández I, Malalana Martínez AM, González
Armengod C, Costarelli V, Millán Santos I, et al. Intrapartum synthetic
oxytocin reduce the expression of primitive reflexes associated with
breastfeeding. Breastfeed Med [Internet] 2015;10(4):209–13. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4410763&tool=
pmcentrez&rendertype=abstract%5Cn.
30. Dahlen HG, Downe S, Wright ML, Kennedy HP, Taylor JY. Childbirth and
consequent atopic disease: emerging evidence on epigenetic effects based on
the hygiene and EPIIC hypotheses. BMC pregnancy childbirth. BMC Pregnancy
and Childbirth. 2016;16(1):4 Available from: http://bmcpregnancychildbirth.
biomedcentral.com/articles/10.1186/s12884-015-0768-9.
31. ACOG Committee on Practice Bulletins - Obstetrics. ACOG practice bulletin
no. 107: induction of labor. Obstet Gynecol. 2009;114(2):386–97.
32. Odendaal HJ. Hyperstimulation of the uterus during the oxytocin stress test.
Obstet Gynecol. 1978;51(3):380–3.
33. Seijmonsbergen-Schermers A, de Jonge A, van den Akker T, Beeckman K,
Bogaerts A, Barros M, et al. Variations in childbirth interventions in high-
income countries: protocol for a multinational cross-sectional study. BMJ
Open. 2018;8(1):e017993 Available from: http://bmjopen.bmj.com/lookup/
doi/10.1136/bmjopen-2017-017993.
34. The Institute for Safe Medication Practices (ISMP). List of high-alert medications
in acute care settings. www.ismp.org . 2014. Available from: http://www.ismp.
org/Tools/highalertmedications.pdf. Last access: June 7th 2019.
35. NICE guidelines committee. NICE Guideline: Intrapartum care for healthy women
and babies. NICE (National Institute for Health and Care Excellence). 2014. p. 1–58,
Available from: https://www.nice.org.uk/guidance/cg55, Updated in 2017: https://
www.nice.org.uk/guidance/cg190. Last access: June 7th 2019.
36. Eggebø TM, Rossen J, Ellingsen L, Heide HC, Muneer S, Westad S. NFOG
Guideline: Augmentation of Labour. NFOG. 2014. p. 1–2. Available from: http://
www.nfog.org/files/guidelines/34%20NGF%20Obst%20Augmentation%20of
%20labour%20Eggeb%C3%B8.pdf.
37. Institute of Obstetricians and Gynaecologists RC of P of I. Clinical strategy
and Programmes division HSE. Clinical practice guideline: oxytocin to
accelerate or induce labour. Health service Executive. 2016; Available from:
https://www.hse.ie/eng/about/who/acute-hospitals-division/woman-infants/
clinical-guidelines/oxytocin-to-accelerate-or-induce-labour.pdf.
38. Dupont C, Carayol M, Le Ray C, Deneux-Tharaux C, Riethmuller D. Oxytocin
administration during spontaneous labor: Guidelines for clinical practice.Guidelines short text. J Gynecol Obstet Hum Reprod. Elsevier Masson SAS.
2017;46(6):539–43 Available from: https://doi.org/10.1016/j.jogoh.2017.04.010.
39. Gross MM, Michelsen C, Vaske B, Helbig S. Intrapartum care working
patterns of midwives: the long road to models of Care in Germany. Z
Geburtshilfe Neonatol. 2018;222(2):72–81.
40. Godfrey M. An evaluation of the guidance for the use of Oxytocin in
maternity services in Ireland [Internet]. State Claims Agency Newsletter,
2015. 2015. p. 2–3. Available from: http://stateclaims.ie/wp-content/uploads/
2015/02/SCA-Newsletter-January-2015.pdf. Last access: June 7th 2019.
41. O’Driscoll K. Active management of labour. BMJ. 1972;4(5837):425 Available
from: http://www.bmj.com/cgi/doi/10.1136/bmj.4.5837.425-c.
42. Arulkumaran S, Gibb D, Lun K, Heng S, Ratnam S. The effect of parity on
uterine activity in labour. Br J Obstet Gynaecol. 1984;91(9):843–8.
43. Friedman E. Primigravid labor; a graphicostatistical analysis. Obstet Gynecol.
1955;6:567–89.
44. Zhang J, Landy HJ, Ware Branch D, Burkman R, Haberman S, Gregory KD,
et al. Contemporary patterns of spontaneous labor with Normal neonatal
outcomes. Obstet Gynecol. 2010;116(6):1281–7 Available from: https://
insights.ovid.com/crossref?an=00006250-201012000-00008.
45. Grantz KL, Gonzalez-Quintero V, Troendle J, Reddy UM, Hinkle SN,
Kominiarek MA, et al. Labor patterns in women attempting vaginal birth
after cesarean with normal neonatal outcomes. Am J Obstet Gynecol. 2015;
213(2):226.e1–6.
46. Lavender T, Hart A, Smyth RM. Effect of partogram use on outcomes for
women in spontaneous labour at term. Cochrane database Syst rev, vol. 6;
2013. Available from: http://doi.wiley.com/10.1002/14651858.CD005461.pub4
47. Bugg GJ, Siddiqui F, Thornton JG. Oxytocin versus placebo or no treatment
for slow progress in the first stage of spontaneous labour. Cochrane
Database Syst Rev. 2008;(2);7(7):CD007123; https://doi.org/10.1002/14651858.
CD007123.pub2.
48. Wei S, Wo BL, Qi H-P, Xu H, Luo Z-C, Roy C, et al. Early amniotomy and early
oxytocin for prevention of, or therapy for, delay in first stage spontaneous
labour compared with routine care. In: Fraser WD, editor. Cochrane
Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 2012.
Available from: http://doi.wiley.com/10.1002/14651858.CD006794.pub3.
49. Begley CM, Gross MM, Dencker A, Benstoem C, Berg M, Devane D. Outcome
measures in studies on the use of oxytocin for the treatment of delay in
labour: A systematic review. Midwifery. Elsevier. 2014;30(9):975–82 Available
from: https://doi.org/10.1016/j.midw.2014.06.005.
50. Stokholm L, Juhl M, Lønfeldt NN, Mikkelsen SH, Obel C, Strandberg-Larsen K.
Obstetric synthetic oxytocin use and subsequent hyperactivity/inattention
problems in Danish children. Acta Obstet Gynecol Scand. 2018; Available
from: http://doi.wiley.com/10.1111/aogs.13344.
51. Wei S, Wo BL, Xu H, Luo ZC, Roy C, Fraser WD. Early amniotomy and early
oxytocin for prevention of, or therapy for, delay in first stage spontaneous
labour compared with routine care. Cochrane Database Syst Rev. 2013;(8):
CD006794; https://doi.org/10.1002/14651858.CD006794.pub4.
52. Cahill AG, Waterman BM, Stamilio DM, Odibo AO, Allsworth JE, Evanoff B,
et al. Higher maximum doses of oxytocin are associated with an
unacceptably high risk for uterine rupture in patients attempting vaginal
birth after cesarean delivery. Am J Obstet Gynecol. 2008;199(1):32.e1–5
Available from: http://linkinghub.elsevier.com/retrieve/pii/
S0002937808002627.
53. NICE guidelines committee. Caesarean section [internet]. NICE (National
Institute for health and care excellence). 2011. Available from: https://www.
nice.org.uk/guidance/cg132. Last access: June 7th 2019.
54. ACOG Committee on Practice Bulletins - Obstetrics. VBAC Guidelines : What
they mean to you and your patients. ACOG Today. 2010;54(4):6-7. Available
online: https://www.acog.org/-/media/ACOG-Today/acogToday0810.
pdf?dmc=1&ts=20190607T1515573842.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
